Effect of radiation fractionation on IDO1 via the NF-κB/COX2 axis in non-small cell lung cancer

• Published in: International immunopharmacology Vol. 124; p. 110956
• Main Authors: Lan, Yanli, Pi, Wenhu, Zhou, Zhangjie, Meng, Yinnan, DanMei, Xu, Yixiu, Xia, Xinhang, WeiWang, Yang, HaiHua, Spring Kong, Feng-Ming
• Format: Journal Article
• Language: English
• Published: Elsevier B.V 01.11.2023
• Subjects: COX2; CRT; D-1MT; IDO1; NSCLC; SBRT; BED; HSP90; Kyn; RT; CRT; NSCLC; OS; IHC; H&E; HRP; H; P-NF-κB; Ctrl; WB; TME; Trp; SBRT; COX2; qPCR; SEM; D-1MT; IDO1
• ISSN: 1567-5769; 1878-1705
• DOI: 10.1016/j.intimp.2023.110956

•IDO1 may be a significant factor associated with adaptive radiation resistance.•COX2 plays a critical role in radiation induced IDO1 upregulation.•D-1MT may sensitize radiation cancer killing by inhibiting IDO1.•Hypofractionated radiation induces less post-therapy immune suppression, more cancer killing than CRT, likely mediated through IDO1-COX2 Pathway. Radiotherapy (RT) is the mainstay treatment modality for lung cancer. We recently reported that conventionally fractionated radiotherapy (CRT) with daily fractionation of 2Gy significantly increased the activity of indoleamine 2,3-dioxygenase (IDO1), a known immune checkpoint, which predicted poorer long-term survival in patients with non-small cell lung cancer (NSCLC), while stereotactic body radiotherapy (SBRT) using fractionation size of 10Gy did not increase IDO1 activity and had better survival. Here we hypothesized that the hypofractionated SBRT kind of dose fraction stimulates host antitumor immunity via downregulating IDO1 in which CRT could not. We tested this hypothesis in vitro and in vivo using 10Gyx1 and 2Gyx8 fractionations in the laboratory. The results demonstrated that, although there was an initial downregulation after RT, the expression of IDO1 was ultimately upregulated by both fractionation regimens. The 10Gyx1 regimen had minimum upregulation, while the 2Gyx8 regimen significantly increased in IDO1 expression which was positively correlated with the elevated expressions of p-NF-κB and COX2. Pharmacological inhibition of COX2 abolished RT-induced IDO1 expression. Furthermore, the IDO1 inhibitor, D-1-methyl-tryptophan (D-1MT), exerted RT-related tumor-killing effects in the NSCLC cell lines and mouse models. These findings suggest that, in addition to being an immune suppressor, IDO1 may serve as an adaptive resistance factor in RT. Furthermore, an unappreciated mechanism may exist, where a larger fraction size might be superior to conventional sizes in cancer treatment. This study may provide a rationale for future research in using IDO1 as a biomarker to personalize RT dose fractionation and COX2 inhibitor to decrease radiation immune suppression from CRT.